

TENNCARE OUTPATIENT PHARMACY BENEFIT COVERAGE CHANGE RE: SUNLENCA AND YEZTUGO EFFECTIVE NOVEMBER 2, 2026

Effective November 2, 2026, the following products below will no longer be covered under the TennCare pharmacy outpatient benefit. Coverage of these medications will transition to the medical benefit for TennCare members.

- **Anti-Infectives**

- Antivirals: HIV Capsid Inhibitors
 - The following will be removed from the PDL and covered under the medical benefit: SUNLENCA oral tablets
 - YEZTUGO and SUNLENCA oral tablets/injectable coverage will fall under the medical benefit for TennCare members

Yeztugo and Sunlenca are lenacapavir-containing products with distinct indications that require close clinical oversight, adherence monitoring, and coordinated care.

- Yeztugo is indicated for HIV-1 pre-exposure prophylaxis (PrEP) in adults and adolescents (≥ 35 kg) at risk of acquiring HIV-1. Patients must be HIV-1 negative before initiating and throughout treatment with Yeztugo.
- Sunlenca is indicated, in combination with other antiretroviral agents, for heavily treatment-experienced adults with multidrug-resistant HIV-1 whose current regimen is failing.

Transitioning coverage to the medical benefit supports enhanced patient safety, ensures appropriate clinical monitoring, and aligns with the level of oversight needed for these therapies. For coverage and billing details, please refer to the patient's specific Managed Care Organization (MCO). A list of TennCare health plans is available at the TennCare Health Plans link below.

TennCare Health Plans: <https://www.tn.gov/tenncare/providers/managed-care-contractors>